A few years ago, Hiren Doshi’s wife Riddhi had to go through a day surgery. It was successfully performed by her OB-Gyn at the world-famous Weill Cornell Medical Center in New York, and she was discharged with some support medication. The next morning, her condition deteriorated and she was unable drink water or swallow food. They spent the next six days going from one referral to another, where no one could provide a correct diagnosis or resolution. It finally landed her at the ER where a doctor was able to conclude that it was inflammation of the esophagus due to doxycycline. She was prescribed simple antacids, which remedied the situation.
While Hiren was relieved that his wife was cured, he was upset and angry.
” Here I am in the most advanced times in evolution, in the most advanced nation in the world in the most advanced healthcare system, and I still couldn’t find quality care.”
– Hiren Doshi
Hiren felt that medicine had become a profession without a soul or compassion.
“I vividly remembered my younger days when the ‘family doctor’ took care of us and attended to us till we got well.” – Hiren Doshi
As a suffering patient, he had to find a more reliable healthcare solution for his family. But as Hiren researched further, he was shocked to learn about the physician’s plight. Their individual and collective suffering was far greater than mine. Most physicians get into their occupation because they liked patient care, but now were experiencing numerous challenges.
Hiren was determined to help fix this dysfunction—both for patients and for physicians.
By occupation, he had been an entrepreneur, building successful companies throughout his entire life. His personal philosophy, instilled to him at a young age, is that “one has to take charge and do something about they change they wish.”
One thing led to another, and finally to the birth of Paragon with a single minded higher purpose to help improve health, vitality and longevity for patients while bringing JOY in lives of physicians, teams and all constituents we work with.
Our determination to change healthcare has only grown stronger. We are proud to have a passionate team committed to a “revolution” in healthcare!
Message From The CEO
Thank you for taking the time to visit our website and taking the time to hear my heart-felt words about Paragon.
We are purposeful.
First and foremost, we are a purposeful organization. Our company’s higher purpose of improving health, vitality and longevity for patients while bringing JOY to lives of physicians, teams and all constituents, is fanatically shared by all Paragon team members. Every decision made by any team member is made with this purpose in mind. While we not a non-profit and have to be economically sustainable, we would like to do it with “conscious capitalism” in mind.
We have a positive culture.
There’s a lot of talk in the corporate world about how culture trumps strategy. We want to exemplify excellence with our values and culture. Not only did our early team collectively define our core values, but our team shares our values deeply and works intently to incorporate them in the workplace everyday. Our entire team tries to do whatever it takes, with customer delight as the focus, ensuring we are continuously innovating and upgrading everything we do, with highest level of integrity so we can sleep well at night and have lots of fun along the way. We take this so seriously that we focus on one of our values in our daily discussion and spend an hour every Friday learning collectively as a team, re-enforcing what matters most.
We are intentional.
We try to be very intentional and strategic about everything we do. We realize that it takes combination of art and science combined with excellent teamwork for things to work. We have ritual of daily team huddle joined by every Paragon team member, where they provide individual updates on performance on various metrics and key challenges faced. We strive hard to build and maintain a cohesive team.
We have goals.
We are very ambitious and goal oriented. Our Big Hairy Audacious Goal (BHAG) is to touch over a million lives and make it a great place to work. We are committed to a “revolution” in healthcare, in our own little way. And we are going to make a difference in the world and do it differently!
If any of this resonates with you, I welcome you to join us as a physician, patient, team member, vendor, partner in our endeavor…
With kindest personal regards,
Paragon Management Team
Holly Furlong, DC
Neil R. Hoyt, Sr.
Guru Ramanathan Ph.D., MBA
Dr. Guru Ramanathan is Chief Innovation Officer and Senior Vice President for Pittsburgh based General Nutrition Corporation (GNC). His responsibilities include Scientific Affairs, Regulatory Compliance, Quality Assurance and Control, Clinical Trials Management, Technology Acquisition, Alliance Management, Product Development and Manufacturing Operations for GNC’s Global Markets.
Dr. Ramanathan’s industry experience spans Clinical care, Pharma, Consumer health, Animal health and the Retail sectors. Prior to his current appointment with GNC, Dr. Ramanathan was a Senior Director for Royal Numico’s US subsidiaries. Before this he was Medical Director for the US subsidiary of Scotia Pharmaceuticals. He has also held various industry consulting, research and teaching appointments in India and the US.
Dr. Ramanathan holds an MBA from Duke University’s Fuqua School of Business focused on global business practices. He earned his Ph.D. from Tufts University in Healthcare Innovation Management.
Dr. Ramanathan is a dentist by discipline specialized in cranio-facial growth and development with over 32 years of clinical, research and industry experience both within and outside the US. He has managed over 100 clinical studies, made more than 40 international scientific presentations, industry-sponsored seminars and workshops at various venues, leading to several publications in peer reviewed journals and consumer magazines.
Stephen C. Schimpff, M.D., FACP
Dr. Schimpff, an Eagle Scout, is a 1963 graduate of Rutgers University where he was a Henry Rutgers Scholar and recipient of the Van Der Poole Award for Excellence in Medicinal Chemistry. He obtained his M.D. degree in 1967 at Yale University Medical School and was inducted into Alpha Omega Alpha, the national medical honor society. His internal medicine internship and residency was at Yale-New Haven Hospital.
He was selected as a Clinical Associate in the Baltimore Cancer Research Center (BCRC) of the National Cancer Institute from 1969-1972. He was a Fellow in the National Institute of Allergy and Infectious Diseases, NIH, from 1972-1973. He is Board certified in Internal Medicine, Medical Oncology and Infectious Diseases.
Dr. Schimpff was Senior Investigator in the National Cancer Institute’s BCRC from 1973 to1982. In 1976 he became Head, Section of Infectious Diseases and Microbiology at the BCRC and from 1979 was, concurrently, Head, Division of Infectious Diseases, Department of Medicine, at the University of Maryland School of Medicine.
He became internationally recognized for his research into the causes, prevention and treatment of infection in cancer patients undergoing aggressive cancer therapy. He has published over 200 scientific articles, reviews and book chapters and has edited three text books, including “Comprehensive Textbook of Oncology,” “Supportive Care in Cancer” and “Infectious Complications in Bone Marrow Transplantation.” Clinically he devoted most of his time to treating patients with acute leukemia and lymphomas and leading a program of infectious diseases for the Cancer Center. He was an early advocate for the concept of “empiric treatment of febrile neutropenia.” His approach, published in The New England of Medicine in 1972, became the gold standard around the world and has saved untold numbers of lives of cancer patients receiving aggressive chemotherapy. He became one of the three or four most recognized leaders worldwide in the field of infection in cancer patients.
He developed a diverse team of physicians, basic and applied scientists, pharmacists, nurses and others to advance this work over a twenty year period. Included were studies of molecular biology of Pseudomonas aeruginosa, animal models of antibiotic efficacy in granulocytopenia, volunteer and patients studies of blood bacteriocidal activity, pharmacokinetic and pharacodynamic evaluations of new and standard agents, applied microbiology especially of gram negative bacteria, molecular epidemiologic evaluations of organism spread from patient to patient, randomized evaluations of new antibiotics and antibiotic combinations, the use of laminar air flow rooms with and without oral non-absorbable microbial gut decontamination, etc. With three colleagues from Europe, he founded the International Anti-microbial Therapy Project Group with an initial membership of 13 centers to conduct randomized trials for treatment and prevention of infection in cancer patients. The work of the group over nearly three decades has been considered of high quality and high relevance. He later, with two European colleagues, founded the Multinational Organization for Supportive Care in Cancer which has its own respected journal and annual meeting now attracting over 1000 per session.
He was promoted to professor of medicine in the School of Medicine in 1979 and granted tenure in 1982. He was also appointed as professor of pharmacology and professor of oncology in 1982. He held an adjunct appointment in the School of Pharmacy
In 1982, he was appointed founding Director of the University of Maryland (Greenebaum) Cancer Center. This was a turnaround situation and within a few years the Center had multiple grants, a broad and growing patient referral base, many patients on study and the recruitment of quality new faculty. The Center would later become an NCI recognized comprehensive cancer center.
In 1985, he was recruited to be Executive Vice President and Chief Operating Officer of the newly created University of Maryland Medical System in Baltimore. This was also a major turnaround situation, the hospital being recently separated from state ownership and university governance. The hospital was essentially a negative acquisition from the state with poor physical and technical status, a demoralized clinical faculty and little community appreciation. Over twenty years it was converted from a failing institution to a robust institution and concurrently the System grew to a twelve hospital system operating throughout much of Maryland. (This remarkable transformation has been documented in the book “Alignment” noted below.)
Dr. Schimpff became Chief Executive Officer of the Medical System’s flagship, the University of Maryland Medical Center, in 1999. The Medical Center admits about 40,000 patients per year, largely for tertiary care, and includes the world’s preeminent trauma center, an NCI designated comprehensive cancer center and one of the country’s largest transplant programs. There are about 5000 staff and 650 residents with an annual budget of over $1 billion; all medical care is provided by faculty of the School of Medicine.
Since quasi-retirement in 2004, Dr. Schimpff has written four books for a general audience. The first, published in 2007 by Nelson Books, is entitled “The Future of Medicine: Megatrends in Healthcare.” It is focused on genomics, vaccines, technology, imaging, stem cells, the operating room and information management along with complementary medicine. He has completed a sequel, “The Future of Health-Care Delivery: Why It Must Change and How It Will Affect You,” which focuses on “healthcare of the future” and the factors that will drive how medical care will be delivered in the coming 5 to 20 years. The book demonstrates how physicians and hospitals must and will change to accommodate these far reaching implications. A portion of the book also focuses on the healthcare reform issues of payment for medical and health care and how reform will impact the delivery of medical care into the future. As noted, Dr Schimpff also teamed with his longtime colleague, Dr Morton Rapoport, to write “Alignment – The Key to Success of the University of Maryland Medical System.” This book, published in 2009, describes the first 25 years since the University of Maryland Hospital was separated from state ownership and university governance and grew from a struggling single hospital into a vibrant multi-hospital system.
His fourth book Fixing The Primary Care Crisis – Reclaiming The Patient-Doctor Relationship and Returning Healthcare Decisions To You and Your Doctor was published in May, 2015. The book reviews the causes of the crisis and then offers some sensible solutions for what is the most critical issue in our dysfunctional healthcare system today. It is his intent and hope that the book will help resolution by engaging the necessary audiences to drive for transformation.
Dr Schimpff and a friend, David Miller, PhD have recently published a book on the early speculators who acquired Canaan Valley, WV from the State of Virginia just after the War of Independence. Called Fortune Seekers in the Promised Land – A Tale of Exploitation and Development in the Canaan Valley and Blackwater Region of West Virginia, it explores how the arrival of the railroad led to wholesale destruction of an important ecosystem and how it is slowly but surely returning, raising the question of the most appropriate public policies for the future.
Dr Schimpff gave the endowed annual Willging Distinguished Lecture entitled “Aging Gracefully” in the fall of 2015. He is using that as a springboard to a new book to be published in late 2017 titled Longevity Decoded – The Seven Secrets to Healthy Aging.
He is deeply committed to advancing patient safety and has served as the consultant to the United States Army to develop their program on mechanisms to interdigitate high technology into improved patient safety in the “operating room of the future.” He has also consulted for the US Army on the “hospital of the future” with special regard to the technologies that will become part of mainstream medical care in the coming years and led the process of the Army’s Telemedicine and Advanced Technology Research Center to develop its strategic plan. Dr Schimpff has previously been a governing board member of two medical technology companies, CytoPulse Sciences, Inc and Salar Inc. and also the chair of their respective scientific advisory committees. He has been chair of the scientific advisory board of Sanovas, Inc. a leading developer of miniaturized diagnostic and treatment techniques and he is a senior adviser to Sage Growth Partners, a health care consulting firm.
He remains a Professor of Medicine (voluntary) at the University of Maryland School of Medicine and he has been a research Professor of Public Policy at the University of Maryland College Park.
At the behest of the University of Maryland, he was the director of a five state, twelve institution consortium proposal to the Department of Homeland Security to build and operate a 500,000 sf biocontainment research institution to be known as the National Bio-Agro Defense Facility designed to study foreign biothreats to the country’s food supply.
In 2017 he was elected as a Master in the of the American College of Physicians, an honor bestowed on only about 50 fellows per year from a membership of about 150,000. He received the ACP Maryland Chapter, Mary Betty Stevens Award for Excellence in Clinical Investigation in 1998. He was senior author of 11 original investigations and an editorial in the Annals of Internal Medicine.
He is a fellow of the American Society of Clinical Oncology and a member of the Infectious Diseases Society of America and the American Association of Cancer Research and has been active in the University Health System Consortium and the Association of American Medical Colleges. He was Treasurer of the American Society of Clinical Oncology from 1985 – 1989 and was a member of the National Board of Medical Examiners for six years.
Dr. Schimpff was chair of the Board of Governors of the National Institutes of Health’s Warren G. Magnuson Clinical Center from January 1999 until 2003; he was a board member since its inception in 1996 and member of the Board’s Executive Committee and chair of the Finance Working Group.
Civic activities have included the Downtown Partnership of Baltimore, Inc. Board of Directors and the March of Dimes, Maryland Chapter, Board of Directors. He was a member for ten years of the University of Maryland School of Pharmacy Board of Visitors. Dr. Schimpff served as a member of the boards of the Maryland Hospital Education Institute; the American Cancer Society, Maryland Division (President from 1990-1992); Maryland Association of Nonprofit Organizations (Chairman, Board of Directors from 1994-1997); the Maryland Hospital Association Board of Directors (1998- 2003); the Easter Seals Society of Maryland (Vice Chairman 1991-1992) and with his wife was co-leader of a Girl Scout Troop in Columbia, Maryland.
Since moving to the Charlestown Retirement Community in 2015, he has done a weekly TV show on health and wellness for the 2000 residents and has been a keynote speaker at the annual Health Expo.
Christopher B. Moore
Mr. Moore joined Massey Quick soon after the firm’s inception. He sits on the firm’s Management and Investment committees providing insight on strategy, management, financial planning, and investments.
His responsibilities include overseeing the firm’s asset allocation and portfolio construction process and he works closely with the Client Advisors to structure client portfolios. He also oversees the Investment Research Team and due diligence process across equity, fixed income, hedge fund, private equity, real estate, and venture capital investments.
Mr. Moore authors the firm’s annual Market Outlook which provides guidance on market and asset class expectations and is a frequent author of topical white papers. He has had a variety of speaking engagements and is a frequent panelist on asset allocation, alternative investing, and due diligence. Bloomberg, The Wall Street Journal and The New York Times have all interviewed Mr. Moore.
He serves as an Advisory Board Member for Bow River Capital Partners, a private equity firm based out of Denver, CO. He is a member of the NJ chapter of the Young Presidents’ Organization (YPO). He is actively involved in fundraising and support for the fight against breast cancer through both the Susan G. Komen Foundation and the Avon Walk for Breast Cancer.
Mr. Baheti’s leadership ensures The Focus Group excels at providing solutions that contain a blend of innovative technology and high quality, scalable services to meet emerging and current market needs. The Focus Group’s most recent success was its healthcare venture, Focus Infomatics, which pioneered the use of cutting edge speech recognition technology and scalable medical transcription services to serve more than 200 premier healthcare corporations and hospitals nationwide. In 2007, Focus Infomatics was acquired by Nuance Communications (NUAN) to bolster their $1 Billion Healthcare Division. Nuance is a global leader in digital speech recognition and its technology is behind Apple’s Siri.
In 2012 , Mr. Baheti founded The Focus Group’s two online learning divisions, Focus EduVation and FEV Tutor after noting many parallels in the K-12 learner market as it related to Online/Blended Learning, Education Technology and 1-to-1 learning initiatives for student achievement.
Mr. Baheti holds a Bachelors of Business Administration (BA) in Finance from The University of Texas at Austin.
Mr. Braverman received his BS from the Wharton School at the University of Pennysylvania. He worked as an Analyst at the Blackstone Group. As a freshman in college in 1999 he started what was to become Nuts.com.
He was a New Jersey Ernst & Young Entrepreneur of the Year winner in 2014 and a National Finalist.
He is an entrepreneur with interests in the real estate and restaurant businesses.
Dhiraj Shah founded Avaap in 2006 to address critical business gaps for organizations that rely on Infor Lawson as their mission-critical ERP. In 2011, Dhiraj made the decision to strategically focus on Infor software solutions. Under Dhiraj’s leadership, the company has experienced significant growth and exceeded its goals every year since its inception. Today, Avaap is among the largest Infor Alliances Partners.
In 2016, Avaap acquired Falcon Consulting, a KLAS-leading Epic Systems implementation and optimization firm. Avaap is the only Infor systems integrator with a dedicated EHR practice, providing healthcare customers with a single source solution for clinical, business and financial applications. Avaap employs more than 400 technology and business professionals across its locations, including offices in Edison, New Jersey, Chicago, St. Paul, MN, Spain, U.K. and Chennai, India. This growth is testament to Dhiraj’s vision and genuine desire to improve customer business practices through strategic partnerships and exceptional software services.
Avaap has earned several accolades including Infor Alliance Partner of the Year in 2014-2016; Infor Cloud and Net-New Sales Partner 2016; Infor Services Partner of the Year in 2013 and Infor 2012 Partner of the Year for Innovation. Avaap has also been recognized for its fast growth, including the Best in Biz award in the medium size business category; NJBIZ’s Fastest Growing Companies in New Jersey and a six-year honoree on the INC. 500 list of fastest growing private companies in the U.S.
Prior to Avaap, Dhiraj held several positions at Lawson Software. He was instrumental in developing Lawson’s offshore strategy by helping establish a global center of excellence in Chennai. He has spoken at numerous industry conferences including Inforum, Infor Partner Summit, INC. 500 conference, and the Kaplan Institute. Dhiraj graduated with honors from New Jersey Institute of Technology with a B.S. in Computer Science and a minor in professional communications. He is an active member of the Young Presidents’ Organization, a global networking organization of successful entrepreneurs.
Dhiraj has the unique talent for leveraging the latest technologies and conceptualizing them into turnkey solutions that drive better efficiency and efficacy for Avaap’s growing customer base. His deep industry knowledge has helped Avaap build a strong presence in the healthcare, manufacturing, retail, and public sector verticals, among others